Baclofen is NOT Recommended for Temporomandibular Joint Pain
Baclofen should not be used for treating temporomandibular joint (TMJ) pain, as it is not supported by current evidence-based guidelines and lacks proven efficacy for this indication.
Why Baclofen is Inappropriate
The most recent and highest quality guideline—the 2023 BMJ international clinical practice guideline on chronic TMD pain—does not include baclofen among any of its recommended interventions 1. This comprehensive guideline systematically evaluated all available therapies and made explicit recommendations based on rigorous evidence synthesis.
What the Guidelines Actually Say About Muscle Relaxants
While older guidelines from 2019 mention "muscle relaxants" as a general first-line option 1, the 2023 BMJ guideline—which supersedes these—conditionally recommends AGAINST acetaminophen with or without muscle relaxants 1. This represents a shift away from muscle relaxant use based on updated evidence.
Baclofen's FDA-Approved Indications
According to the FDA label, baclofen is indicated specifically for:
- Spasticity from multiple sclerosis
- Spinal cord injuries and diseases
- NOT for skeletal muscle spasm from rheumatic disorders 2
The FDA explicitly states: "Baclofen tablets are not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders" 2. TMJ disorders fall into the category of musculoskeletal pain conditions, not spasticity disorders.
What You SHOULD Use Instead
Strong Recommendations (Use These First):
- Cognitive behavioral therapy (CBT) with or without biofeedback 1
- Therapist-assisted mobilization 1
- Manual trigger point therapy 1
- Supervised jaw exercises and stretching 1
- Usual care (home exercises, stretching, reassurance, education) 1
Conditional Recommendations (Consider These Next):
Clinical Pitfalls to Avoid
Don't confuse spasticity with muscle tension: Baclofen treats central nervous system spasticity (hyperreflexia, excessive muscle contraction from CNS pathology), not the muscle tension or myofascial pain seen in TMD 2.
Sedation risk: Baclofen causes significant CNS depression, sedation, and has additive effects with other CNS depressants 2. This side effect burden is not justified given the lack of evidence for TMD.
Withdrawal syndrome: Baclofen requires dose tapering when discontinuing due to potential withdrawal 3, making it particularly problematic for a condition where it has no proven benefit.
Gabapentin is also not recommended: The 2023 guideline specifically issued a conditional recommendation AGAINST gabapentin for TMD pain 1, despite it being mentioned in older guidelines as a neuromodulatory option 1.
The Evidence Gap
While baclofen has been studied for trigeminal neuralgia 3 and has shown effects in other pain conditions like acute low-back syndrome 4, there is no quality evidence supporting its use in TMD. The comprehensive systematic review and network meta-analysis underlying the 2023 BMJ guideline did not find sufficient evidence to recommend baclofen for this indication 1.
Bottom line: Start with strongly recommended non-pharmacologic interventions (CBT, manual therapy, supervised exercises) and if medication is needed, consider NSAIDs combined with CBT rather than muscle relaxants like baclofen 1.